Polymorphisms in the IL28B gene (rs12979860, rs8099917) and the virological response to pegylated interferon therapy in hepatitis D virus patients

Basit Öğe Kaydı
dc.contributor.authorYilmaz, Bulent
dc.contributor.authorCan, Guray
dc.contributor.authorUcmak, Feyzullah
dc.contributor.authorArslan, Ali Osman
dc.contributor.authorSolmaz, Ihsan
dc.contributor.authorUnlu, Ozan
dc.contributor.authorDuzenli, Selma
dc.date.accessioned2020-03-26T19:25:40Z
dc.date.available2020-03-26T19:25:40Z
dc.date.issued2016
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractAim : Few data are available regarding the effects of interleukin 28B (IL28B) polymorphisms in chronic hepatitis D (CHD) patients. This study investigated the relationship between IL28B polymorphisms and the response of patients with CHD infections to pegylated interferon (PEG-IFN) therapy. Materials and methods : A total of 101 CHD patients were selected, 80 of whom (46 males; median age 41 years) satisfied the inclusion criteria and were enrolled in the study. Thirty-seven patients were treated with peg-IFNa for at least 12 months and were followed for a median of 18 months (range, 12-30 months). The primary treatment endpoint was the suppression of HDV replication, as documented by the loss of detectable HDV RNA in serum. Geno-typing was used to analyse the IL28B polymorphisms rs12979860 and rs8099917 according to the virological response. Results : After treatment, a sustained viral response (SVR) was achieved in 19 (51%) of the patients treated with PEG-INF. The IL28B genotypes in the 80 patients were as follows : CC in 36 (45%), CT in 33 (41%) and TT in 11 (14%) for rs12979860, and GG in 4 (5%), GT in 27 (34%) and TT in 49 (61%) for rs8099917. SVR was achieved in 5 (26%), 10 (53%) and 4 (21%) patients with CC, CT and TT at rs12979860, respectively, and one (5%), nine (47%) and nine (47%) patients with GG, GT and TT at rs8099917, respectively. There were differences in the SVR among genotypes (rs12979860 and rs8099917; chi-squared test, p = 0.047). Conclusion : IL28B predicts the PEG-IFN response in patients with CHD infection.en_US
dc.identifier.endpage210en_US
dc.identifier.issn0001-5644en_US
dc.identifier.issue2en_US
dc.identifier.pmid27382939en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage206en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/33887
dc.identifier.volume79en_US
dc.identifier.wosWOS:000384746300006en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherUNIV CATHOLIQUE LOUVAIN-UCLen_US
dc.relation.ispartofACTA GASTRO-ENTEROLOGICA BELGICAen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectchronic hepatitis Den_US
dc.subjectPEG-IFN therapyen_US
dc.subjectIL28Ben_US
dc.titlePolymorphisms in the IL28B gene (rs12979860, rs8099917) and the virological response to pegylated interferon therapy in hepatitis D virus patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu